Editorials Sulfonylureas as second line treatment for type 2 diabetes BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3041 (Published 18 July 2018) Cite this as: BMJ 2018;362:k3041 Article Related content Metrics Responses Peer review Related articles Research Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study Published: 18 July 2018; BMJ 362 doi:10.1136/bmj.k2693 ResearchSulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events See more NICE responds to article on patient organisations declaring financial interests BMJ February 15, 2019, 364 l733; DOI: https://doi.org/10.1136/bmj.l733 Primary care networks: five minutes with . . . Sohail Munshi BMJ February 15, 2019, 364 l754; DOI: https://doi.org/10.1136/bmj.l754 Sixty seconds on . . . waiting times BMJ February 15, 2019, 364 l752; DOI: https://doi.org/10.1136/bmj.l752 Medical cannabis: no NHS patients have benefited from law change, say campaigners BMJ February 15, 2019, 364 l753; DOI: https://doi.org/10.1136/bmj.l753 Johnson and Johnson will be first US pharma company to reveal a drug’s price in TV advertisement BMJ February 15, 2019, 364 l751; DOI: https://doi.org/10.1136/bmj.l751
